MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$1,793,381
EPS
-$0.22
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
57,621
-49,380*
365,053
409,937
General and administrative
1,247,077
671,628.5*
1,739,174
1,634,195
Impairment of in-process research and development
-
-9,323,951.5*
18,647,903
-
Total operating expenses
1,304,698
-8,701,703
20,752,130
2,044,132
Gain from operations
-1,304,698
8,701,703*
-20,752,130
-2,044,132
Interest expense
-132,512
-121,130*
-131,350
-130,036
Fair value option loss on convertible notes
-344,000
-
-
-
Change in fair value of warrant liabilities
-16,000
-
-
-
Change in fair value of equity payable
28,171
81,807.5*
-226,262
37,149
Pre-tax net gain
-
8,498,765.5*
-20,657,218
-2,211,317
Income tax benefit (provision)
-
425,829.5*
-851,659
0
Net gain
-1,793,381
8,072,936
-19,805,559
-2,211,317
Basic EPS
-0.22
1.354
-2.56
-0.46
Diluted EPS
-0.22
1.354
-2.56
-0.46
Basic Average Shares
8,095,921
5,963,943*
7,740,678
4,814,115
Diluted Average Shares
8,095,921
5,963,943*
7,740,678
4,814,115
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net gain
-$1,793,381
Change in fair value of
warrant liabilities
-$16,000
Gain from operations
-$1,304,698
Fair value option
loss on convertible...
-$344,000
Interest expense
-$132,512
Change in fair value of
equity payable
$28,171
Total operating
expenses
$1,304,698
General and
administrative
$1,247,077
Research and development
$57,621
Buy us a coffee
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)